News & Updates

Show Multimedia Only

Allopurinol reduces cirrhosis-related complications

15 Jan 2024 by

Use of allopurinol 300 mg helps prevent the incidence of overall complications associated with liver cirrhosis, reports a study.

Allopurinol reduces cirrhosis-related complications

15 Jan 2024

Antivirals underutilized after curative resection of HBV- or HCV-related HCC

15 Jan 2024 by

Antiviral therapy is associated with substantial improvements in long-term overall survival (OS) but severely underutilized after curative hepatic resection in patients with hepatitis B virus (HBV)– or hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC), a real-world study involving predominantly Asian patients has shown.

Antivirals underutilized after curative resection of HBV- or HCV-related HCC

15 Jan 2024

$Patients with autoimmune hepatitis at higher risk of osteoporotic fracture$

Patients with autoimmune hepatitis at higher risk of osteoporotic fracture

12 Jan 2024

The risk of osteoporotic fracture seems greater in patients with autoimmune hepatitis (AIH), reveals a recent study. In addition, those with cirrhosis and long-term use of glucocorticoids appear to be at much greater risk.

Patients with autoimmune hepatitis at higher risk of osteoporotic fracture

12 Jan 2024

Fibrosis screening prompts positive lifestyle shifts

05 Jan 2024

Screening for liver fibrosis appears to spur lifestyle improvements especially among people who screened positive for the condition, according to a study.

Fibrosis screening prompts positive lifestyle shifts

05 Jan 2024

Aspirin reduces liver fat, improves markers of inflammation, fibrosis

04 Jan 2024 by

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) – previously called nonalcoholic fatty liver disease (NAFLD) – but without cirrhosis, who were treated with daily low-dose aspirin, had significant reductions in liver fat for 6 months in a new trial.

Aspirin reduces liver fat, improves markers of inflammation, fibrosis

04 Jan 2024

NAFLD ups risk of memory impairment, hippocampal damage

20 Dec 2023

The presence and severity of nonalcoholic fatty liver disease (NAFLD) may contribute to cognitive impairment, as well as hippocampal structure and functional abnormalities, suggests a study.

NAFLD ups risk of memory impairment, hippocampal damage

20 Dec 2023

Original New Drug Application Approvals by US FDA (16-30 November 2023)

13 Dec 2023

New drug applications approved by US FDA as of 16-30 November 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 November 2023)

13 Dec 2023

NAFLD progression may raise ESLD risk

13 Dec 2023

Histological disease progression in patients with nonalcoholic fatty liver disease (NAFLD) is significantly associated with a higher rate of developing incident end-stage liver disease (ESLD) but not with all-cause mortality, a study has shown.